Targeted therapy

May 28, 2021
Doctor and patient reviewing test results

Now Enrolling: EA2192/APOLLO for Pancreatic Cancer

This phase II study, led by Dr. Kim Reiss Binder, is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes
March 31, 2021
Doctor patient skin exam

Now Enrolling: EA6194 for Operable Melanoma

This phase II study, led by Dr. Ahmad Tarhini, is testing neoadjuvant treatment with pembrolizumab alone versus pembrolizumab and an investigational drug called CMP-001
January 14, 2020

Institution Spotlight: Fox Chase Cancer Center

A Standing Main Member of ECOG-ACRIN since 1971